Cidara Therapeutics, Inc. (CDTX)
Jan 7, 2026 - CDTX was delisted (reason: acquired by MRK)
221.38
+0.06 (0.03%)
Inactive · Last trade price on Jan 6, 2026

Cidara Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jan '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
6,97429472548588
Market Cap Growth
4719.92%309.50%32.57%-36.04%-3.62%-30.74%
Enterprise Value
6,5561712735452
Last Close Price
-26.8815.8815.1325.4040.00
PS Ratio
-230.623.082.311.717.28
PB Ratio
15.381.80-8.75-3.753.938.20
P/TBV Ratio
16.511.80--3.938.20
EV/Sales Ratio
-133.801.180.121.104.28
Debt / Equity Ratio
0.010.02-0.59-0.080.240.74
Asset Turnover
-0.010.410.380.730.19
Quick Ratio
4.403.870.740.931.911.22
Current Ratio
4.624.250.901.092.111.48
Return on Equity (ROE)
-68.70%-219.59%--608.89%-263.05%-297.06%
Return on Assets (ROA)
-29.35%-40.46%-29.54%-22.29%-38.91%-69.41%
Return on Invested Capital (ROIC)
-36.75%-69.72%--204.17%-116.57%-131.62%
Return on Capital Employed (ROCE)
-37.80%-55.20%6974.20%-359.80%-102.30%-328.70%
Earnings Yield
-2.65%-57.76%-31.94%-62.00%-50.14%-82.06%
FCF Yield
-1.91%-60.08%-31.94%-52.79%-29.84%-62.13%
Buyback Yield / Dilution
-229.65%-45.26%-25.15%-33.18%-26.22%-38.83%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q